



## Medical Policy Manual **Approved Rev: Do Not Implement until 6/2/26**

### Methoxy Polyethylene Glycol-Epoetin Beta (Mircera®)

#### IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

#### POLICY

#### INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indications

Mircera is indicated for the treatment of anemia associated with chronic kidney disease (CKD) in:

- Adult patients on dialysis and adult patients not on dialysis.
- Pediatric patients 3 months to 17 years of age on dialysis or not on dialysis who are converting from another erythropoiesis-stimulating agent (ESA) after their hemoglobin level was stabilized with an ESA.

All other indications are considered experimental/investigational and not medically necessary.

#### DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

##### Continuation Requests

Chart notes, medical records, or laboratory results of current (within the last 30 days) hemoglobin level.

#### COVERAGE CRITERIA

Note: Requirements regarding pretreatment hemoglobin level exclude values due to a recent transfusion. All members must be assessed for iron deficiency anemia and have adequate iron stores (defined as a serum transferrin saturation [TSAT] level greater than or equal to 20% within the prior 3 months) or are receiving iron therapy before starting Mircera. Members may not use Mircera concomitantly with other erythropoiesis stimulating agents (ESAs) or with hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs).

#### Anemia Due to Chronic Kidney Disease (CKD)

Authorization of 12 months may be granted for the treatment of anemia due to CKD in adult members with pretreatment hemoglobin (Hgb) less than 10 grams per deciliter (g/dL).

## Medical Policy Manual **Approved Rev: Do Not Implement until 6/2/26**

Authorization of 12 **months** may be granted for the treatment of anemia due to CKD in pediatric members 3 months to 17 years of age who are converting from another ESA after their hemoglobin level was stabilized (e.g., Hgb level of 10 to 12 g/dL) with an ESA.

### CONTINUATION OF THERAPY

Note: Requirements regarding current hemoglobin level exclude values due to a recent transfusion. All members must be assessed for iron deficiency anemia and have adequate iron stores (defined as a serum transferrin saturation [TSAT] level greater than or equal to 20% with the prior 3 months) or are receiving iron therapy before continuation of treatment with Mircerca. Members may not use Mircerca concomitantly with other erythropoiesis stimulating agents **or with hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs)**.

### Anemia Due to Chronic Kidney Disease (CKD)

Authorization of 12 **months** may be granted for continued treatment of anemia due to chronic kidney disease in members with current hemoglobin less than 12 g/dL.

### APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

### ADDITIONAL INFORMATION

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

### REFERENCES

1. Mircerca [package insert]. St. Gallen, Switzerland: Vifor (International) Inc.; April 2024.
2. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *Kidney Int.* 2012;Suppl 2:279-335.

**EFFECTIVE DATE** 6/2/2026

ID\_CHS\_2025